---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Indication"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Indication. Topics: Indication under study: adults with CIDP; Eligible population: phase 3 CAPTIVATE inclusion criteria; Patient groups enrolled: treated, refractory, and treatment-naive. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/indication"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Indication under study: adults with CIDP

> “The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

> “The CAPTIVATE trial is a single, two-part, randomized withdrawal global Phase 3 trial of claseprubart in patients with CIDP.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-2.1.2.5-2"></a>

### Eligible population: phase 3 CAPTIVATE inclusion criteria

> “Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel. CIDP Disease Activity Status (CDAS) score ≥ 3 at screening. Must be neurologically stable. Must have an INCAT score between 2 and 9 inclusive.”
> “Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin [IVIg] or subcutaneous immunoglobulin [SCIg]) alone or Ig (IVIg or SCIg) plus oral corticosteroids”
> “Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.”
> “Refractory participants who have had treatment failure (worsening) or an inadequate response to Ig and/or oral corticosteroids”
> “Treatment naïve with no history of prior treatment for CIDP.”
> “Ages Eligible for Study 18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.5-3"></a>

### Patient groups enrolled: treated, refractory, and treatment-naive

> “Evaluating claseprubart in SoC- Refractory CIDP patients, in addition to a broader CIDP patient population including SoC-Treated and SoC-Naïve”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Patients aged 18–75 years with confirmed CIDP are administered an IV loading dose of claseprubart followed by 300mg SC Q2W in Part A.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
